LOTTE BIOLOGICS

ABOUT

LOTTE BIOLOGICS is a global CDMO providing comprehensive services from development to commercial production. With advanced manufacturing capabilities in the U.S. and a state-of-the-art facility under construction in Korea, the company delivers top-quality biopharmaceutical manufacturing solutions to global clients.

At the Syracuse Bio Campus in New York, LOTTE BIOLOGICS provides high-quality GMP manufacturing services for drug substances. The facility offers a total production capacity of 40,000L. Additionally, the campus includes extensive analytical QC testing laboratories and warehouse facilities that have received approval from over 62 regulatory agencies worldwide. LOTTE BIOLOGICS is also advancing into a new area of expertise with a one stop Antibody-Drug Conjugate (ADC) service, expected to be fully operational in early 2025.

Looking ahead to 2030, LOTTE BIOLOGICS is constructing three advanced bio plants in Songdo, South Korea. With construction of the first plant already underway and expected to be operational by 2026, each facility will feature eight 15,000L stainless steel bioreactors for large-scale commercial production. Collectively, these plants will provide a manufacturing volume exceeding 360,000L in bioreactor capacity.

Through our commitment to delivering innovative medicines to patients worldwide, LOTTE BIOLOGICS aims to become a Global Top 10 CDMO company in the biopharmaceutical industry.

For more information please visit : www.lottebiologics.com

New York Syracuse Bio Campus : 6000 Thompson Rd, East Syracuse, NY 13057, United States
Songdo Bio Campus : 418 Songdo-dong, Yeonsu-gu, Incheon, South Korea
Headquarters : LOTTE World Tower, 300 Olympic-ro, Songpa-gu, Seoul, South Korea